Replies to post #456504 on Zeev's Turnips Patch-No Politics (ZEEV)

[madrose1]

08:31 MYOG Myogen Reports Positive Top Line Results for Ambrisentan LFT Rescue Study In Pulmonary Arterial Hypertension (36.99 )

Co today announced positive top line results of the AMB-222 study, an open-label study of ambrisentan in patients with pulmonary arterial hypertension who have previously discontinued bosentan and/or sitaxsentan treatment due to liver function abnormalities. Based on results to date and the properties of ambrisentan, Myogen believes that, if ambrisentan is ultimately approved, it may offer significant clinical benefit to PAH patients not provided by other pulmonary arterial hypertension therapies.